p[0.012) and post-treatment TURP (RRR[41.63, p<0.001) increased risk of mixed incontinence.
INTRODUCTION AND OBJECTIVES:
Owing to toxicity concerns with combination therapy, there has been a contemporary trend toward use of monotherapeutic brachytherapy (BT) for the treatment of localized prostate cancer (PC). Standard of care calls for a dose prescription sufficient to attain a D90 of !140 Gy with iodine, or a biological equivalent dose (BED) of 154 Gy2. For patients with insufficient dose delivered as determined on post-implant dosimetry, practitioners may initiate adjuvant external beam radiation (EBRT) or hormonal therapy (HT) to improve oncological outcomes, particularly in intermediate or high risk disease patients. We sought to quantify the marginal benefit gained by the addition of HT as a function of BED.
METHODS: Among 2277 men who underwent BT AE EBRT from 1990 to 2015, 688 (30%) men with intermediate risk disease were identified. We evaluated the influence of receiving HT at various maximum BED cut-points with respect to freedom from biochemical failure (FFbF), as defined by Phoenix criteria (nadir PSA þ 2 ng/ml). Ten-year FFbF was estimated by Kaplan Meier method. A cut-point of BED <150 with HT was set as the reference standard against which we tested other BED levels in the absence of HT. Chi-square test was used to evaluate difference in 10-year FFbF between the various BED levels.
RESULTS: Median follow up was 8.3 years (range, 2.8-21.8). Median age was 67 years (range, 41-84) and median PSA was 8.4 ng/ ml (range, 1-20). The 10-year FFbF for men receiving BED <150 with HT was 81.6%. Compared to this reference group, FFbF was worse for men with BED <150 (p[.002) and <160 (p[.021) without HT. However, this statistical significance was lost at BED <170 (p[.319) and for higher cut-points as there was no difference to the baseline group (BED <150 with HT) in terms of FFbF.
CONCLUSIONS: In the case of a post-dosimetry BED <150, intermediate risk patients gain an oncologic benefit from the addition of 6 months of HT, equivalent to receiving a BED of at least 170 Gy2 without HT. Alternatively, this marginal benefit of 20 BED from the addition of adjuvant HT also corresponds to receiving 2 weeks of EBRT at 1.8 Gy/ fraction.
Source of Funding: none

MP72-16 COMPARISON BETWEEN 3 TECHNIQUES FOR THE TREATMENT OF RADIATION-INDUCED HEMORRHAGIC CYSTITIS: GREENLIGHT XPS LASER, HOLMIUM LASER, AND MONOPOLAR ELECTROCOAGULATION
Isma€ el Chelghaf*, Quentin Alimi, Karim Bensalah, Peyronnet Benoit, Nantes, France INTRODUCTION AND OBJECTIVES: Radiation-induced hemorrhagic cystitis is the most frequent sequelae of pelvic radiotherapy. Its induce frequent hospitalizations, surgical interventions, and blood transfusions. Multiple treatments have been tried, but the management of this damages is difficult and ill-defined.
The aim of the study was to compare efficacy and safety of coagulation for telangiectasias and hemorrhagic cystitis, with Greenlight XPS laser, Holmium laser, and monopolar electrocoagulation. RESULTS: 59 procedures, for 44 patients, have been included. 18 procedures were realized by GreenLight XPS laser, 16 by monopolar coagulation, and 25 by Holmium laser, with higher major toxicity rate for monopolar group (RTOC/EORTC grade>2 : 0% vs 37,5% vs 12% : p[0.008). Clavien-Dindo!3 intraoperative and post-operative complications rate, was statistically higher in monopolar group (p[0.01 and p[0,0006, table) , like length of hospital stay (p[0.02).
Median follow-up was 13, 38, and 58 months (p<0.0001), and hematuria recurrence rate was higher in Holmium laser group (39% vs 50% vs 80% ; p[0.02). However survived without treatment (surgery or hyperbaric oxygen) were comparable between the 3 groups (p[0.56).
CONCLUSIONS: For patient suffering from hematuria, caused by radiation-induced cystitis, efficacy of coagulation by GreenLight XPS laser seemed higher than monopolar or Holmium laser. These results must be confirmed by long-term data and more cases. 
